Apnimed appoints Yee as senior exec
By HME News Staff
Updated 9:57 AM CDT, Wed September 20, 2023
CAMBRIDGE, Mass. – Apnimed, a pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea and related disorders, has appointed John Yee, MD, MPH, as senior vice president of medical affairs. Dr. Yee will lead Apnimed’s efforts to engage and inform the clinical community about the company’s lead drug candidate AD109, as well as other pipeline assets, as they progress through clinical development toward commercial launch. “We are thrilled to welcome John with his experience and expertise in new product launches and expansions as our Phase 3 registration trials get underway for AD109, our first-in-class oral therapeutic for OSA,” said Larry Miller, MD, CEO of Apnimed. “John’s experience will be essential in informing clinicians about the emerging clinical data for AD109 in the treatment of OSA.” Yee has more than 25 years of leadership experience at leading biotechnology, pharmaceutical and health care technology companies, and at a major academic medical center. Prior to joining Apnimed, he served as chief medical officer at Sobi North America.
Comments